Cinryze 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IAIN/0095 
A.3 - Administrative change - Change in name of the 
06/10/2022 
AS or of an excipient 
amended 
on 
SmPC, 
Labelling and 
PL 
IAIN/0094 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
13/07/2022 
n/a 
amended PMF in the marketing authorisation dossier 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
T/0093 
Transfer of Marketing Authorisation 
15/03/2022 
17/05/2022 
SmPC, 
Labelling and 
PL 
PSUSA/10104
Periodic Safety Update EU Single assessment - 
10/02/2022 
n/a 
PRAC Recommendation - maintenance 
/202106 
human C1-esterase inhibitor 
IAIN/0092/G 
This was an application for a group of variations. 
28/01/2022 
17/05/2022 
Annex II and 
PL 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
Page 2/26 
 
 
 
 
 
 
 
 
 
 
 
 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0091 
B.I.b.2.e - Change in test procedure for AS or 
06/01/2022 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
II/0089 
B.II.e.1.a.3 - Change in immediate packaging of the 
02/12/2021 
n/a 
Page 3/26 
 
 
 
 
 
 
 
 
 
 
 
finished product - Qualitative and quantitative 
composition - Sterile medicinal products and 
biological/immunological medicinal products 
IAIN/0088 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
12/07/2021 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IAIN/0087/G 
This was an application for a group of variations. 
04/05/2021 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0086 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
23/02/2021 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
II/0082/G 
This was an application for a group of variations. 
18/02/2021 
24/01/2022 
Annex II 
B.I.d.1.b.3 - Stability of AS - Change in the storage 
conditions - Change in storage conditions of the AS 
Page 4/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
B.I.a.1.e - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product 
B.I.a.1.e - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product 
IAIN/0085 
B.II.b.2.c.1 - Change to importer, batch release 
01/02/2021 
24/01/2022 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0081 
C.I.z - Changes (Safety/Efficacy) of Human and 
13/10/2020 
24/01/2022 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
IA/0083 
A.7 - Administrative change - Deletion of 
08/10/2020 
n/a 
manufacturing sites 
IAIN/0080 
B.IV.1.a.1 - Change of a measuring or administration 
25/09/2020 
n/a 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Page 5/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Device with CE marking 
IAIN/0079 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
24/07/2020 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IB/0078 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
22/06/2020 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IAIN/0077 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
20/05/2020 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IAIN/0076 
B.II.b.2.c.1 - Change to importer, batch release 
23/03/2020 
31/07/2020 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
PSUSA/10104
Periodic Safety Update EU Single assessment - 
16/01/2020 
n/a 
PRAC Recommendation - maintenance 
/201906 
human C1-esterase inhibitor 
IB/0075 
B.V.a.1.b - PMF - Inclusion of a new, updated or 
20/12/2019 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Page 6/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First-time inclusion of a new PMF NOT affecting the 
properties of the FP 
IAIN/0074 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
03/12/2019 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
II/0071/G 
This was an application for a group of variations. 
28/11/2019 
n/a 
B.I.a.1.e - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product 
B.I.a.2.c - Changes in the manufacturing process of 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
Page 7/26 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.e.1.a.3 - Change in immediate packaging of the 
finished product - Qualitative and quantitative 
composition - Sterile medicinal products and 
biological/immunological medicinal products 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IAIN/0072/G 
This was an application for a group of variations. 
08/07/2019 
n/a 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Page 8/26 
 
 
 
 
 
 
 
 
 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
II/0069 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
20/06/2019 
31/07/2020 
SmPC and PL 
new quality, preclinical, clinical or pharmacovigilance 
data 
IAIN/0070/G 
This was an application for a group of variations. 
18/03/2019 
n/a 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IB/0067/G 
This was an application for a group of variations. 
20/02/2019 
n/a 
Page 9/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
Page 10/26 
 
 
 
 
 
 
 
IB/0068 
B.II.b.4.a - Change in the batch size (including batch 
30/01/2019 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
II/0064 
B.I.b.2.d - Change in test procedure for AS or 
17/01/2019 
n/a 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
IA/0066 
B.II.e.7.b - Change in supplier of packaging 
24/10/2018 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
IAIN/0063 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
02/05/2018 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IAIN/0062 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
19/04/2018 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IA/0061 
A.4 - Administrative change - Change in the name 
20/03/2018 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
Page 11/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturer of a novel excipient 
IAIN/0060 
B.II.b.2.c.1 - Change to importer, batch release 
20/03/2018 
27/08/2018 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0059 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
16/03/2018 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
II/0058/G 
This was an application for a group of variations. 
15/03/2018 
n/a 
B.I.a.2.c - Changes in the manufacturing process of 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
PSUSA/10104
Periodic Safety Update EU Single assessment - 
11/01/2018 
n/a 
PRAC Recommendation - maintenance 
/201706 
human C1-esterase inhibitor 
IB/0057/G 
This was an application for a group of variations. 
09/11/2017 
n/a 
Page 12/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
B.II.b.5.a - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
IB/0056 
B.II.b.3.z - Change in the manufacturing process of 
27/10/2017 
n/a 
the finished or intermediate product - Other variation 
II/0048 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
14/09/2017 
27/08/2018 
SmPC, 
The term Unit (U) is replaced by International Unit (IU) for 
new quality, preclinical, clinical or pharmacovigilance 
Labelling and 
the product potency throughout the product information. 
data 
PL 
Historically assigned potency values were relative to an in-
house reference standard whereby 1 Unit (U) is equal to 
the mean quantity of C1 inhibitor present in 1 ml of normal 
human plasma.  An international reference standard (IU) 
has now been implemented where IU is also defined as the 
amount of C1 inhibitor present in 1 ml of normal human 
plasma. 
IAIN/0054 
B.IV.1.a.1 - Change of a measuring or administration 
23/06/2017 
n/a 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
IA/0053/G 
This was an application for a group of variations. 
01/06/2017 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
Page 13/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
changes to an approved test procedure 
IB/0052 
B.V.a.1.b - PMF - Inclusion of a new, updated or 
26/05/2017 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
First-time inclusion of a new PMF NOT affecting the 
properties of the FP 
IA/0051 
B.I.a.1.f - Change in the manufacturer of AS or of a 
15/05/2017 
n/a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
IB/0049/G 
This was an application for a group of variations. 
04/05/2017 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.II.b.2.z - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Other variation 
IAIN/0050/G 
This was an application for a group of variations. 
24/03/2017 
n/a 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
Page 14/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
II/0045 
Extension of Indication in children with hereditary 
15/12/2016 
26/01/2017 
SmPC, 
Please refer to the CHMP AR. 
Labelling and 
PL 
angioedema (HAE) to include the treatment and pre-
procedure prevention of angioedema attacks from 2 
years and the routine prevention of angioedema 
attacks from 6 years; as a consequence, sections 
4.1, 4.2, 4.8, 5.1, 5.2, 6.5 and 6.6 of the SmPC are 
updated. The key messages of educational materials 
in the Annex II, the Package Leaflet and the 
Labelling are updated in accordance. In addition, an 
update of regional information in module 3.2.R due 
to the proposed dose recommendation for children is 
submitted. 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
PSUSA/10104
Periodic Safety Update EU Single assessment - 
12/01/2017 
n/a 
PRAC Recommendation - maintenance 
/201606 
human C1-esterase inhibitor 
IA/0047/G 
This was an application for a group of variations. 
20/10/2016 
26/01/2017 
Annex II 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
Page 15/26 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
IA/0044 
B.II.b.2.a - Change to importer, batch release 
21/06/2016 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0043 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
01/06/2016 
n/a 
Page 16/26 
 
 
 
 
 
 
 
 
 
 
 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
R/0040 
Renewal of the marketing authorisation. 
01/04/2016 
26/05/2016 
SmPC, Annex 
II, Labelling 
and PL 
IAIN/0042 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
29/04/2016 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
PSUSA/10104
Periodic Safety Update EU Single assessment - 
14/01/2016 
n/a 
PRAC Recommendation - maintenance 
/201506 
human C1-esterase inhibitor 
II/0039 
Early discontinuation of the Cinryze Registry Study 
17/12/2015 
n/a 
0624-401 and replacement by the Icatibant Outcome 
Survey (IOS), Disease Registry for compliance with 
an Annex II.D condition. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
IG/0603/G 
This was an application for a group of variations. 
03/12/2015 
26/05/2016 
SmPC, Annex 
II, Labelling 
Page 17/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.1 - Administrative change - Change in the name 
and PL 
and/or address of the MAH 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
IB/0035 
B.I.a.4.z - Change to in-process tests or limits 
06/11/2015 
n/a 
applied during the manufacture of the AS - Other 
variation 
IG/0621 
C.I.8.a - Introduction of or changes to a summary of 
16/10/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IAIN/0038 
B.II.b.1.a - Replacement or addition of a 
09/10/2015 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0032/G 
This was an application for a group of variations. 
27/07/2015 
26/05/2016 
Annex II 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
IA/0034 
B.II.d.2.a - Change in test procedure for the finished 
24/07/2015 
n/a 
Page 18/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Minor changes to an approved test 
procedure 
IA/0033 
B.II.d.2.a - Change in test procedure for the finished 
16/07/2015 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0030/G 
This was an application for a group of variations. 
30/04/2015 
n/a 
B.I.b.1.a - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits for medicinal products subject to 
OCABR 
B.II.b.5.a - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
IAIN/0031 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
09/04/2015 
n/a 
amended PMF in the marketing authorisation dossier 
Page 19/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IAIN/0029 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
16/02/2015 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IB/0028/G 
This was an application for a group of variations. 
14/01/2015 
n/a 
B.II.e.1.b.z - Change in immediate packaging of the 
finished product - Type of container - Other variation 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
PSUV/0027 
Periodic Safety Update 
09/01/2015 
n/a 
PRAC Recommendation - maintenance 
PSUV/0023 
Periodic Safety Update 
24/07/2014 
30/09/2014 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
the variation to terms of the Marketing Authorisation(s)’ for 
Page 20/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUV/0023. 
IAIN/0025 
C.I.8.a - Introduction of or changes to a summary of 
02/07/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IAIN/0024 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
11/06/2014 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IB/0022 
B.II.b.z - Change in manufacture of the Finished 
01/06/2014 
n/a 
Product - Other variation 
IAIN/0021 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
11/04/2014 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
II/0017 
Submission of the final study report of study 0624-
20/03/2014 
n/a 
Please refer to the scientific discussion Cinryze 
203: “an open-label single-dose study to evaluate 
the response and pharmacokinetics / 
pharmacodynamics of different doses of CINRYZE for 
treatment of acute angioedema attacks in children 
less than 12 years of age with hereditary 
angioedema” in order to fulfil the requirement of 
article 46 of the paediatric regulation. No change to 
the product information was required. 
EMEA/H/C/001207/II/0017 for further information. 
Page 21/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IB/0019 
B.II.b.4.f - Change in the batch size (including batch 
13/03/2014 
n/a 
size ranges) of the finished product - The scale for a 
biological/immunological medicinal product is 
increased/decreased without process change (e.g. 
duplication of line) 
IB/0018/G 
This was an application for a group of variations. 
20/02/2014 
30/09/2014 
SmPC, 
B.II.e.z - Change in container closure system of the 
Finished Product - Other variation 
B.IV.1.b - Change of a measuring or administration 
device - Deletion of a device 
Labelling and 
PL 
IAIN/0020/G 
This was an application for a group of variations. 
17/02/2014 
n/a 
C.I.9.a - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
QPPV and/or QPPV contact details and/or back-up 
procedure 
C.I.9.b - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change(s) in the 
safety database and/or major contractual 
arrangements for the fulfilment of PhV obligations, 
and/or change of the site undergoing PhV activities 
C.I.9.c - Changes to an existing pharmacovigilance 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
Page 22/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the PhV system 
PSUV/0016 
Periodic Safety Update 
09/01/2014 
n/a 
PRAC Recommendation - maintenance 
II/0014 
Changes to Drug product specification to fulfill Annex 
19/09/2013 
30/09/2014 
SmPC, Annex 
II condition 002. 
Changes in the due date for conditions 003 and 004. 
B.II.d.z - Change in control of the Finished Product - 
Other variation 
II and PL 
IAIN/0015 
B.IV.1.a.1 - Change of a measuring or administration 
18/07/2013 
n/a 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
IAIN/0013/G 
This was an application for a group of variations. 
19/03/2013 
n/a 
C.I.9.a - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
QPPV 
C.I.9.c - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the 
back-up procedure of the QPPV 
C.I.9.e - Changes to an existing pharmacovigilance 
system as described in the DDPS - Changes in the 
major contractual arrangements with other persons 
or organisations involved in the fulfilment of 
pharmacovigilance obligations and described in the 
DD 
C.I.9.h - Changes to an existing pharmacovigilance 
Page 23/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
IAIN/0012/G 
This was an application for a group of variations. 
06/03/2013 
n/a 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
II/0011 
B.I.a.3.c - Change in batch size (including batch size 
15/11/2012 
n/a 
ranges) of AS or intermediate - The change requires 
assessment of the comparability of a 
biological/immunological AS 
IB/0005 
B.II.d.2.b - Change in test procedure for the finished 
09/11/2012 
n/a 
product - Deletion of a test procedure if an 
alternative method is already authorised 
II/0003 
To calibrate an in house concentrate standard 
20/09/2012 
25/10/2012 
Annex II 
against WHO 1 international standard for c1- 
inhibitor. This variation is to fulfil Annex II condition 
001. 
Page 24/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.z - Quality change - Finished product - Other 
variation 
IAIN/0010 
B.II.b.2.b.1 - Change to batch release arrangements 
14/09/2012 
25/10/2012 
Annex II and 
and quality control testing of the FP - Not including 
PL 
batch control/testing 
IAIN/0009/G 
This was an application for a group of variations. 
22/08/2012 
n/a 
C.I.9.e - Changes to an existing pharmacovigilance 
system as described in the DDPS - Changes in the 
major contractual arrangements with other persons 
or organisations involved in the fulfilment of 
pharmacovigilance obligations and described in the 
DD 
C.I.9.h - Changes to an existing pharmacovigilance 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
IA/0008 
B.I.a.4.b - Change to in-process tests or limits 
17/08/2012 
n/a 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
IB/0007 
B.IV.1.a.1 - Change of a measuring or administration 
17/08/2012 
25/10/2012 
SmPC, 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
Labelling and 
PL 
IAIN/0004/G 
This was an application for a group of variations. 
12/07/2012 
n/a 
Page 25/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
II/0001 
Amendment (timetable extension) of the conditions 
19/04/2012 
22/05/2012 
Annex II 
of the Marketing Authorisation 
B.II.z - Quality change - Finished product - Other 
variation 
IB/0002/G 
This was an application for a group of variations. 
14/04/2012 
22/05/2012 
SmPC, 
Labelling and 
PL 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
B.II.f.1.a.1 - Stability of FP - Reduction of the shelf 
life of the finished product - As packaged for sale 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
Page 26/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
